NASDAQ:INVA Innoviva (INVA) Stock Price, News & Analysis $19.07 -0.34 (-1.75%) (As of 09/6/2024 08:48 PM ET) Add Compare Share Share Today's Range$18.83▼$19.5850-Day Range$16.33▼$19.6952-Week Range$12.22▼$19.85Volume711,300 shsAverage Volume588,183 shsMarket Capitalization$1.19 billionP/E Ratio8.59Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Innoviva alerts: Email Address Innoviva MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish18.43% of Float Sold ShortDividend StrengthN/ASustainability-0.33Upright™ Environmental ScoreNews Sentiment0.37Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.55 out of 5 starsMedical Sector853rd out of 909 stocksPharmaceutical Preparations Industry396th out of 424 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Innoviva.Read more about Innoviva's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted18.43% of the float of Innoviva has been sold short.Short Interest Ratio / Days to CoverInnoviva has a short interest ratio ("days to cover") of 23.1, which indicates bearish sentiment.Change versus previous monthShort interest in Innoviva has recently increased by 1.42%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldInnoviva does not currently pay a dividend.Dividend GrowthInnoviva does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInnoviva has received a 60.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Private equity funds investing in the pharmaceuticals industry" product. See details.Environmental SustainabilityThe Environmental Impact score for Innoviva is -0.33. Previous Next 1.9 News and Social Media Coverage News SentimentInnoviva has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Innoviva this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for INVA on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Innoviva insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.40% of the stock of Innoviva is held by insiders.Percentage Held by Institutions99.12% of the stock of Innoviva is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Innoviva's insider trading history. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Innoviva is 8.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.38.Price to Earnings Ratio vs. SectorThe P/E ratio of Innoviva is 8.59, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 123.52.Price to Book Value per Share RatioInnoviva has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Innoviva's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?Click Here to learn how to get in now >>> About Innoviva Stock (NASDAQ:INVA)Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Read More INVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INVA Stock News HeadlinesSeptember 4, 2024 | seekingalpha.comInnoviva's Rollercoaster: Critical Care Bets With Respiratory BackingSeptember 4, 2024 | finance.yahoo.comInnoviva to Participate in Upcoming Investor ConferencesSeptember 9, 2024 | Paradigm Press (Ad)Kamala is Planning What?! Trump in DangerA former CIA advisor just released this shocking expose on Kamala Harris. What Kamala and her puppet masters are planning for Trump is not only evil… But could trigger the biggest constitutional crisis in our country.August 5, 2024 | investorplace.comTBPH Stock Earnings: Theravance Biopharma Beats EPS, Misses Revenue for Q2 2024July 31, 2024 | investorplace.comINVA Stock Earnings: Innoviva Misses EPS, Beats Revenue for Q2 2024July 31, 2024 | stocknews.com2 Hot Biotech Stocks to Watch This MonthJuly 25, 2024 | seekingalpha.comTop 5 Value Stocks For A Big Tech Pullback (SA Quant)June 27, 2024 | investorplace.com3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented SurgeSeptember 9, 2024 | Paradigm Press (Ad)Kamala is Planning What?! Trump in DangerA former CIA advisor just released this shocking expose on Kamala Harris. What Kamala and her puppet masters are planning for Trump is not only evil… But could trigger the biggest constitutional crisis in our country.June 21, 2024 | seekingalpha.comInnoviva: Potentially OvervaluedJune 3, 2024 | businesswire.comInnoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 10, 2024 | finance.yahoo.comInnoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed AnalysisMay 10, 2024 | finance.yahoo.comInnoviva First Quarter 2024 Earnings: EPS: US$0.58 (vs US$0.51 in 1Q 2023)May 8, 2024 | investorplace.comINVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | businesswire.comInnoviva to Participate in the BofA Securities Health Care ConferenceApril 24, 2024 | finance.yahoo.comInnoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024April 24, 2024 | businesswire.comInnoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024April 22, 2024 | finance.yahoo.comShould Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?See More Headlines Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2024Today9/08/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CUSIP88338T10 CIK1080014 Webwww.inva.com Phone(650) 238-9600Fax650-827-8690Employees112Year Founded1996Profitability EPS (Most Recent Fiscal Year)$2.22 Trailing P/E Ratio8.59 Forward P/E Ratio38.14 P/E GrowthN/ANet Income$179.72 million Net Margins44.00% Pretax Margin46.29% Return on Equity33.26% Return on Assets18.05% Debt Debt-to-Equity Ratio0.67 Current Ratio12.70 Quick Ratio11.40 Sales & Book Value Annual Sales$310.46 million Price / Sales3.84 Cash Flow$3.39 per share Price / Cash Flow5.63 Book Value$10.64 per share Price / Book1.79Miscellaneous Outstanding Shares62,560,000Free Float61,571,000Market Cap$1.19 billion OptionableOptionable Beta0.57 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Pavel Raifeld C.F.A. (Age 40)Chief Executive Officer Comp: $868.65kMr. Stephen Basso M.B.A. (Age 58)Chief Financial Officer Comp: $336.43kMs. Marianne Zhen CPA (Age 55)Chief Accounting Officer & Secretary Comp: $645.05kMs. Patricia M. Drake (Age 58)Chief Commercial Officer-Innoviva Specialty Therapeutics, Inc. Key CompetitorsArcutis BiotherapeuticsNASDAQ:ARQTOcular TherapeutixNASDAQ:OCULPhathom PharmaceuticalsNASDAQ:PHATKiniksa PharmaceuticalsNASDAQ:KNSASupernus PharmaceuticalsNASDAQ:SUPNView All CompetitorsInstitutional OwnershipChase Investment Counsel CorpBought 6,000 shares on 8/19/2024Ownership: 0.128%Systematic Financial Management LPSold 183,956 shares on 8/16/2024Ownership: 3.026%Creative PlanningBought 2,872 shares on 8/16/2024Ownership: 0.035%Caxton Associates LPBought 72,716 shares on 8/15/2024Ownership: 0.173%The Manufacturers Life Insurance Company Sold 2,148 shares on 8/15/2024Ownership: 0.045%View All Institutional Transactions INVA Stock Analysis - Frequently Asked Questions How have INVA shares performed this year? Innoviva's stock was trading at $16.04 at the start of the year. Since then, INVA stock has increased by 18.9% and is now trading at $19.07. View the best growth stocks for 2024 here. How were Innoviva's earnings last quarter? Innoviva, Inc. (NASDAQ:INVA) released its quarterly earnings data on Wednesday, July, 31st. The biotechnology company reported $0.68 EPS for the quarter. The biotechnology company had revenue of $99.90 million for the quarter. Innoviva had a trailing twelve-month return on equity of 33.26% and a net margin of 44.00%. Who are Innoviva's major shareholders? Innoviva's top institutional investors include Dimensional Fund Advisors LP (7.50%), Renaissance Technologies LLC (6.93%), Pacer Advisors Inc. (5.38%) and Systematic Financial Management LP (3.03%). Insiders that own company stock include Pavel Raifeld and Innoviva, Inc. View institutional ownership trends. How do I buy shares of Innoviva? Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some other companies that Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE) and Vertex Pharmaceuticals (VRTX). This page (NASDAQ:INVA) was last updated on 9/9/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredWall Street Insider Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredCan Apple’s AI News Make You Rich?September 20th 2024: AI’s “iPhone Moment” Apple is making a major move on Friday, September 20th. And what ...Banyan Hill Publishing | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innoviva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
